Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a promising company in the biopharmaceutical industry, particularly in the field of diabetes treatment. With its lead candidate cadisegliatin, which has Breakthrough Therapy Designation, vTv is well-positioned to potentially address the unmet need for safe and effective adjunctive therapies for type 1 diabetes. The company has a strong clinical pipeline and strategic collaborations to support its growth, and its financials, while showing some increase in operating expenses, are still sufficient to fund operations for several years. With a potential peak sales estimate of $840M and upcoming Phase 3 trial completion and readout, vTv Therapeutics has a positive outlook for potential future success.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company with a pipeline focused on metabolic diseases, specifically type 1 diabetes. However, recent clinical trials have shown mixed results and the company faces competition from emerging curative treatments for T1D, limiting the potential market for their drug. There is also uncertainty around the long-term efficacy and safety of their lead drug, cadisegliatin, and as a result, the stock may face volatility in the short-term. Financially, the company has a high cash burn rate and limited revenue streams, potentially putting them at risk for future funding needs.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.